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This report summarises the surveillance of lead exposure in children in England 
from 1 January to 31 December 2018. 
 
A case is defined as a child: 
• with a blood lead concentration ≥0.48μmol/L (equivalent to ≥10μg/dl), as 
detected in a UK Accreditation Service (UKAS) accredited biochemistry 
or toxicology laboratory 
• aged under 16 years at the time of first elevated blood lead 
concentration 
• resident in England. 
 
Key points 
• 45 cases of lead exposure in children were notified to Public Health 
England (PHE) in 2018 
• most cases (73%) were directly notified to LEICSS by participating 
laboratories; 11 were notified to PHE through other routes 
• the median delay between a specimen being drawn and a case being 
entered onto HPZone for transfer to the local HPT to initiate public health 
action was 8 days 
• the number of cases detected was lower than the expected incidence of 
lead exposure based on international population survey data 
•  the average detection rate for England between 2015 and 2018 was 
3.76 cases per million children aged 0-15 years, although there was 
large regional variation between PHE Centres 
• cases were typically 1-4 years of age, male, and resident in more 
deprived areas 
• the median blood lead concentration of cases was 0.82μmol/L (16.98 
µg/dL) in 2018. 
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Key messages and recommendations 
• lead is a persistent environmental contaminant that can cause toxicity even at low 
blood lead concentrations - there is no safe lower threshold of exposure 
• children exhibiting pica* or more hand to mouth behaviour in environments with lead 
hazards are likely at highest risk of exposure 
• clinicians should be aware of important sources of lead exposure, children most at 
risk, and presenting symptoms/signs of exposure 
• Public Health England is proposing that the public health intervention level for lead 
is lowered from ≥10μg/dL (≥0.48μmol/L) to ≥5μg/dL (≥0.24μmol/L) for children 
under 16 years and for pregnant women; PHE will work with stakeholders and then 
advise from when these changes will take effect, which is anticipated in 2020  
• cases with a blood lead concentration above the public health intervention level for 
lead should be notified to PHE health protection teams for active public health case 
management 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* The persistent ingestion of non-nutritive substances at an age where this is developmentally inappropriate 
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Background 
Exposure to lead can result in severe multi-system toxicity.  How this toxicity manifests 
depends on both the blood lead concentration (BLC), and how rapidly BLC rises.  Overt 
manifestations of toxicity (i.e. lead poisoning), such as anaemia or abdominal pain, 
accompany higher lead concentrations, eg BLC>1.93μmol/L (>40µg/dl)* [1].  Lead 
exposures resulting in a lower BLC may not cause such apparent symptoms, but still 
cause harm, particularly to the central nervous system.  Decreased intellectual function 
and possibly other neuro-behavioural problems such as shortening of attention span 
and disruptive behaviour are associated with BLCs even below 0.48µmol/L (10µg/dl) 
[1,2].  Timely removal or abatement of the exposure source is the mainstay of case 
management, but symptomatic children, and children with blood lead concentration 
greater than 1.93μmol/L may also require chelation therapy [2]. 
Successful primary prevention efforts – targeted at reducing the use of lead in paints and 
fuels, regulation of lead concentrations in drinking water, planning controls and 
remediation of lead in soil, and control of industry emissions – have resulted in a fall in 
BLC in children. However, lead is a persistent contaminant, therefore children can still be 
exposed to lead already in the environment. Since the removal of lead from petrol, 
ingestion rather than inhalation has been the most common route of exposure in high 
income countries, particularly from flakes and dust from exposed leaded paint [2]. (Leaded 
paint had wide domestic use in the UK before gradual withdrawal from the 1960s onwards 
[3] and was banned for sale in 1992.)
Children with developmental disorders have been found to have higher blood lead 
concentrations than other children [4]; such children are at higher risk of exposure due to 
increased mouthing (or “pica”) behaviour [5] leading to increased ingestion of lead, eg from 
paint flakes, or lead in soil.   Iron deficiency may further increase susceptibility to lead 
toxicity [6]. Other important potential routes of exposure in children are ingestion of lead-
contaminated water, contaminated soil or dust, fuel-containing lead vehicle emissions, 
herbal medicine preparations, consumer products not meeting regulatory standards (eg 
paint on toys, lead crystal glassware) and secondary exposure from parental hobbies or 
occupations (eg resulting in children being exposed to lead dust on work-clothing) [1]. 
There are no recent survey data estimating how many children in England are exposed 
to lead, but international population survey data may be used for estimates; a survey 
conducted in France in 2008/9** [7] estimated 0.09% of 1-6 year-olds had a BLC 
≥0.48µmol/L (≥10µg/dl), and 1.5% a BLC ≥0.24µmol/L (≥5µg/dl). A survey in the USA in 
2013/14 [8] estimated 0.5% of 1-5 year-olds had a BLC ≥0.24µmol/L (≥5µg/dl).  
* Both µmol/L and µg/dL units are commonly used internationally to express blood lead concentrations, where 1 µg/dl =
0.0483µmol/L.  Divide the concentration in µg/dl by 20.7 to obtain the concentration in µmol/L.
** France banned white lead-based interior paint in 1909; thus exposures from this source would be expected to be 
lower than in the UK.  
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Comparison with historic data strongly suggests a substantial fall in average BLCs [8]. 
However, population lead exposure is strongly influenced by setting, so these findings 
give only a broad indication of the potential situation in England.   
Lead exposure is diagnosed by a blood test to measure the blood lead concentration.  
Because signs and symptoms of lead exposure are non-specific, an evidence review for 
population screening was carried out by the National Screening Committee in 2018. A  
systematic population screening programme was not recommended [9] because of 
concerns about testing and treatment and the lack of up to date population data 
(alongside evidence of a steady decline in lead exposure over time). Case detection 
therefore depends on clinicians having a high clinical suspicion, for example due to the 
home circumstances of the child increasing the risk of lead exposure, and subsequently 
ordering a blood test. Surveillance of cases identified by clinicians offers a means of 
gathering intelligence to guide public health action to prevent further cases of exposure. 
The Lead Exposure in Children Surveillance System (LEICSS) 
Public Health England (PHE) coordinates LEICSS, a national surveillance system for children 
resident in England.  Formal surveillance of lead exposure in children in 
England was initiated in 2010 by the Surveillance of Raised Blood Lead Levels in 
Children (SLiC) study, a joint research project between the British Paediatric Surveillance 
Unit and the Health Protection Agency (the forebear to PHE).  The SLiC study authors 
recommended implementation of a laboratory-based surveillance system in order to  
facilitate timely public health management of cases of lead poisoning in children [10].  
A pilot system, the Lead Poisoning in Children (LPIC) surveillance system, was therefore 
instigated in 2014.  LPIC was then permanently implemented in 2016 following 
successful evaluation of the pilot, and its name changed to LEICSS to recognise 
broader aims of prevention of lead exposure in children, in addition to the rapid 
recognition of cases of lead poisoning.   
A PHE working group oversees LEICSS management, and a steering group with 
additional representatives from participating laboratories, academia, and NHS clinical 
toxicology, oversee system aims and development (see Steering and Working Group 
Members below). LEICSS is one component of the Environmental Public Health Surveillance 
System (EPHSS) operated by PHE as part of Environmental Public Health Tracking, and the 
steering group and working group report to the PHE Environmental 
Public Health Tracking Board. More information about Environmental Public Health 
Tracking and EPHSS can be found here: 
https://www.gov.uk/government/publications/environmental-public-health-surveillance-system. 
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LEICSS aims are: 
• to facilitate timely public health action for individual cases, as the mainstay of
treatment for cases of lead exposure is rapid removal of the putative source of
exposure.
• the system should also meet population level surveillance objectives, to inform
public health action to reduce the incidence of lead exposure in children in England,
such as by identifying at risk geographic areas or populations, and identification of
current and emerging sources of exposure.
Case reporting to LEICSS 
LEICSS is a passive surveillance system that integrates reports of incident (newly 
detected) cases of lead exposure in children from 2 sources:   
• cases reported to PHE directly from a testing biochemistry/toxicology laboratory, or
• searching HPZone* for cases first reported from a non-PHE source (eg the
managing clinician or an environmental health officer) to a local PHE Health
Protection Team (HPT)**, or from other PHE departments (eg PHE CRCE
Environmental Hazards and Emergencies) and not reported to LEICSS by
laboratories participating in surveillance
Case notification to PHE is voluntary but encouraged for case management and 
surveillance purposes. 
* HPZone is the public health case management system used in England by PHE Health Protection
Teams when investigating and managing public health threats to their local populations.
** HPTs are frontline units responsible for investigating and managing public health threats to their 
populations. 
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Case reports from biochemistry and toxicology laboratories 
Reports of cases meeting the following case definition are referred to as ‘laboratory-
detected’ cases. 
A laboratory-detected case is defined as a child: 
• with a blood lead concentration ≥0.48μmol/L (equivalent to ≥10μg/dl), as detected in
a UK Accreditation Service (UKAS) accredited biochemistry or toxicology laboratory
• aged under 16 years at the time of first elevated blood lead concentration
• resident in England.
LEICSS surveillance staff enter case details onto HPZone following notification. The 
relevant local HPT is then alerted to investigate and manage the case. This route of 
notification to the investigating HPT has been found to be more timely than waiting for 
notification from other sources involved in treating the case eg the managing 
clinician [11].   
‘HPZone-detected’ cases 
HPZone-detected cases are those that are/were: 
• managed as cases diagnosed with ‘toxic exposure to lead’ by a health protection
team based in England
• aged under 16 years at the time of notification to the health protection team
• resident in England
• not initially notified to LEICSS by a participating biochemistry/toxicology laboratory
Blood lead concentration data are not routinely recorded on HPZone in a way that 
makes them available for analyses by LEICSS for these cases. 
The Supra-regional Assay Service (SAS) Trace Elements laboratories network, 
and other reporting laboratories 
A group of highly specialised diagnostic laboratories, the SAS, provide a referral 
network for specialised laboratory investigations in the UK.  Blood lead concentration 
is measured in six SAS Trace Elements laboratories in England, and it is estimated 
they perform the vast majority of such tests nationally. All six SAS laboratories 
participate in LEICSS, and a partnership between the SAS-associate laboratory in 
Wales (Cardiff Toxicology Laboratory) has been developed to alert LEICSS of 
England residents whose blood lead concentration may be determined in Cardiff. 
Other, non-SAS but accredited laboratories have also agreed to report cases to 
LEICSS; these are typically located in larger NHS Trusts or are private laboratories. 
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Public health management of cases 
A BLC of ≥0.48μmol/L (or ≥10μg/dl) is the current threshold (‘public health intervention 
level’) for public health case management in England. HPTs will take steps to 
systematically identify and remove the potential source(s) of lead exposure in cases, 
following guidance in the PHE Lead Action Card [12]. This involves liaison and 
involvement with other PHE stakeholders, such as the Environmental Hazards and 
Emergencies department, and non-PHE stakeholders, such as the responsible clinician 
and local authority where the case resides.  General information on lead and incident 
management (updated August 2019) can be found on the PHE website.  
Purpose of this report 
This report provides a summary of data extracted from the national LEICSS dataset for 
cases of child lead exposure in residents of England reported to Health Protection 
Teams during 1 January – 31 December 2018. As the number of cases in each year is 
small, we have compared the 2018 metrics to the previous 2015-2017 three-year 
average, where relevant, using data from cases with report dates between 1 January – 
31 December for each of these years. 
Figures are correct at the time of publication and may be subject to change as new 
information about cases becomes available.  
This report and previous year’s annual report and other surveillance reports are 
available at: https://www.gov.uk/government/publications/lead-exposure-in-children-
surveillance-reports 
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Surveillance data indicators
Detection of cases of lead exposure in children in England, and support for timely case
notification for public health action
Number of unique cases:
There were 45 unique cases detected in 2018. Seventy-six percent of cases were direct
laboratory reports to LEICSS, slightly lower than the 2015-17 average of 79% (Table 1).
Table 1. Count and percentage of LEICSS cases, by reporting route to LEICSS,
England 2018, and 2015-17
Route of detection by
LEICSS
Count of cases 2018*
(% of total)
Count of cases*
2015-17 (% of
total)
Direct laboratory reports 34 (76) 91 (79)
HPZone search 11 (24) 24 (21)
Total 45 115
* Based on date case entered onto HPZone
Timeliness of reporting of lab-detected cases to LEICSS and notification of Health
Protection Teams
For the laboratory detected cases, the median delay between the date of specimen
collection and the date the case was entered onto HPZone (as a proxy for date of report
to HPTs) was 8 days, consistent with the 2015-17 median of 9 days (Table 2).
Table 2. Time between specimen collection and entry of case onto HPZone for
case management for lab-detected LEICSS cases, England 2018, and 2015-17
Year Cases Cases
with valid
data*
Median
days delay
LQ - UQ
2018 34 31 8 6-13
2015-17 91 82 9 7-14
* Cases where both a valid specimen date and a valid date of entry onto to HP Zone were extracted from
HPZone; LQ – Lower Quartile, UQ – Upper Quartile
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Occurrence and trends of cases of lead exposure in children
Count and detection rate (by LEICSS) of cases by PHE Centre and year
The number of cases detected in 2018 decreased slightly compared to 2017 (Table 3),
although there is significant under-ascertainment of cases and therefore this should not
be interpreted as a reduction in incidence.‡  The largest reduction in case detection was
observed in the North West in 2018 (3 cases detected compared to 11 in 2017); case
detection increased in the East and West Midlands, East of England and South West.
The average detection rate for England between 2015 and 2018 was 3.76 cases per
million children aged 0-15 years, although there was large regional variation; the
detection rate was 11 times higher in Yorkshire and Humber (11.80 cases per million)
compared to the North East (1.06 cases per million) (Table 3, Figure 1).
Variation in case detection over time and place is more likely to be due to differences in
testing of children at risk and reporting by laboratories, rather than a change in the
number of children exposed to lead hazards. Additionally, the total cases each year is
relatively small, and is therefore prone to change due to random variation, meaning
longer-term observation is required to confirm a trend.
‡  A note regarding detection rate
Because lead exposure below the level causing overt toxicity results in few or non-specific 
symptoms, surveillance of clinically reported cases is likely to under-ascertain the number of 
affected children. International population surveys, which more accurately estimate the 
number of children exposed to lead, suggest an expected incidence of cases of paediatric 
lead exposure higher than detected through LEICSS [7,8]. The figures reported here should 
not therefore be considered representative of the true incidence of child lead exposure in 
England. Various factors affecting case ascertainment are also likely to be driving the 
variation in regional detection rates. For instance, PHE is aware of a system introduced by 
Leeds SAS laboratory (based in Yorkshire and Humber) to actively prompt clinicians to 
consider testing for lead exposure in children whose blood is being tested for suspected iron 
deficiency, where that child is also known to have pica [13]. There is also active engagement 
of local clinicians by this laboratory. The 90% increase in testing and case reporting in this 
region following the introduction of this system demonstrates that differences in clinician 
awareness and testing rate strongly influence case ascertainment  (potentially more so than 
differences in the frequency of lead hazards in the environment between regions). Testing of 
cases in laboratories not reporting cases to LEICSS may also explain part of the regional 
variation in case ascertainment, though SAS labs perform the large majority of BLC tests in 
children in England. Non-reporting of cases by participating laboratories may also have
(more rarely) occurred. Irregular case entry onto HPZone may have prevented some cases 
being detected by our search, though cases first notified to LEICSS are entered using a 
standard procedure. Estimating area-specific testing rates would aid the interpretation of 
case detection rates but is difficult given the supra-regional catchment of SAS laboratories.
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Table 3. Count and percentage of LEICSS cases, and average detection rate† of
cases (per million 0-15 year old children) by PHE Centre and year of notification,
England 2015-2018
Region Cases2015 (%)
Cases
2016 (%)
Cases
2017 (%)
Cases
2018 (%)
Cases
2015-18
(%)
Average
detection rate¥
of cases (per
million per
year) 2015-18
South East* 6 (18) 0 (0) 4 (8) 3 (7) 13 (8) 1.94
London* 5 (15) 7 (21) 10 (20) 12 (27) 34 (21) 4.69
South West 2 (6) 0 (0) 2 (4) 4 (9) 8 (5) 2.05
West
Midlands* 2 (6) 3 (9) 3 (6) 4 (9) 12 (8) 2.61
East
Midlands 1 (3) 0 (0) 0 (0) 3 (7) 4 (3) 1.13
North West 4 (12) 6 (18) 11 (22) 3 (7) 24 (15) 4.34
North East 1 (3) 0 (0) 1 (2) 0(0) 2 (1) 1.06
Yorkshire and
the Humber* 9 (27) 12 (36) 16 (33) 12 (27) 49 (31) 11.80
East of
England 3 (9) 5 (15) 2 (4) 4(9) 14(9) 2.8
ENGLAND 33 33 49 45 160 3.76
† Should not be interpreted as an estimate of incidence – see “Note regarding detection rate” page 10;
¥ The numerator for this indicator is incident cases in 2015-18, and the denominator is the summed mid-year
estimate of the 0-15 population for 2017 multiplied by 4. Cases allocated to PHE Centre according to postcode of
residence;
* PHE Centres where a SAS laboratory that participates in the surveillance system is situated.
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Figure 1 Average detection rate† of LEICSS cases (per million 0-15 year old
children) by PHE Centre, England 2015-2018
† Should not be interpreted as an estimate of incidence – see “Note regarding detection rate” page 10.
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Count and detection rate of cases by gender and age 
The majority of cases in 2018 were male (64%), consistent with the 2015-2017 average 
(70%) (Table 4). Across all age groups the detection rate was higher in males than 
females (Figure 2). This gender disparity is also evident in some international survey 
findings [8], and may reflect a pre-disposition for males to behaviours or comorbidities 
that result in lead exposure (such as autism [14], itself associated with pica [15]), or a 
greater susceptibility to lead toxicity, and hence clinical presentation [16].   
Table 4. Count and percentage of LEICSS cases by sex, England, 2018, and 2015-17 
Sex Count of cases 2018 (%) Count of cases 2015-17 (%) 
Female 14 (31) 31 (27) 
Male 29 (64) 80 (70) 
Unknown 2 (4) 4 (4) 
Total 45 115 
The highest case detection rate was in children aged 1-4 years in males and females 
(Figure 2); 60% of cases were aged 1-4 years in 2018, consistent with the 3-year 
average (56%) (Table 5). Approximately one third of cases in 2018 were aged 5-11 
years, similar to the 2015-2017 average.  There were few cases in the youngest and 
oldest age groups; no cases were detected aged under 1 year in 2018. The high 
percentage of cases in pre-school age children may reflect a greater vulnerability to 
lead exposure due to mouthing behaviours, as ingestion of lead containing substances 
(particularly from deteriorating paint) is likely to be the predominant route of exposure in 
children [2], and mouthing behaviour is common in this age group. Alternatively, 
children in this age group may be tested more frequently. For the adolescents, it is 
unknown what the common exposure sources are. They may be detected after 
exposure pathways other than pica are explored.  
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Table 5. Count and percentage of LEICSS cases by age group*, England, 2018, 
and 2015-2017 
Age group 
Count of 
cases 
2018 (%) 
Count of cases 
2015-17 (%) 
Under 1 year 0 (0) 3 (3) 
1-4 years 27 (60) 64 (56) 
5-11 years 14 (31) 43 (38) 
12-15 years 4 (9) 5 (4) 
Total 45 115 
*Age at date of entry onto HPZone
Figure 2. Average case age-gender* specific detection rate† per million 0-15 year old 
children per year, England 2015-2018 (n=154 cases with gender and age data) 
* Age at date of entry onto HPZone;
† The numerator for this indicator is the count of age-gender specific incident cases in 2015-18, and the
denominator is the summed mid-year estimate of the age-gender specific 0-15 year old population for 2017
multiplied by 4.
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Percentage of cases by quintile of index of multiple deprivation (IMD) status 
IMD provides a measure of deprivation, evaluated across seven domains*, measured at 
the area-level. Seventy-eight percent of cases in 2018 lived in areas in the two most 
deprived quintiles of IMD, slightly higher than the previous three-year average (69%) 
(Figure 3); this is higher than expected given that 45% of the English population aged 0-
15 years reside in areas failing within these two quintiles.**  These observations are 
similar to patterns of lead exposure by socioeconomic status in US national survey 
data [8], and may reflect greater exposure to lead containing hazards, a higher 
frequency of co-morbidities (eg iron deficiency anaemia) or other factors pre-disposing 
to lead toxicity, and/or a greater tendency for clinician testing of children from deprived 
areas.   
Figure 3  Percentage of LEICSS cases in each quintile of index of multiple deprivation¥, 
England 2018 and 2015-17. 
¥ Index of multiple deprivation (IMD) assigned to the Lower-level Super Output
Area of the cases’ residential postcode, using IMD scores from 2015
* See: https://www.gov.uk/government/statistics/english-indices-of-deprivation-2015
** Calculated using ONS mid-year estimate populations for England, assigned to deciles of IMD 2015: 
https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/adhocs/006518deathsa
ndpopulationsbyindexofmultipledeprivationimddecileenglandandwales2001to2015.  
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Blood lead concentrations of laboratory-detected cases 
The median blood lead concentration (BLC) in 2018 was 0.82 μmol/L(16.98 µg/dL), 
similar to the 2015-17 median (0.78 μmol/L(16.15 µg/dL)) (Table 7).  Ninety-two percent 
(data not shown) of blood lead concentrations were <1.93μmol/L(<40 µg/dL) in 2015-
2018, a concentration most consistent with either being asymptomatic, or with non-
specific neuro-behavioural clinical manifestations [1], indicating these children were 
detected based on high index of clinical suspicion.   
Table 7.  Blood lead concentration (μmol/L) of laboratory-detected LEICSS cases, 
England, 2018, 2015-2017 
Year 
Cases 
with 
data/total 
cases 
Min.* Max. Median Lower Quartile 
Upper 
Quartile Mean 
2018 34/34 0.5 2.81 0.82 0.59 1.17 0.97 
2015-17 95/95** 0.48 17.59 0.78 0.55 1.09 1.13 
* Only children with a BLC≥0.48μmol/L were eligible for notification to LEICSS
** Includes four HPZone-detected cases subsequently reported to LEICSS by participating laboratories 
with blood lead specimen dates prior to/on the same day as date of report to PHE HPTs.
Children whose death was attributed to lead exposure 
This information is taken from data extracted from the PHE HPZone case management 
system to the LEICSS dataset.  Only deaths attributed partly or wholly to lead exposure 
are shown, and only in cases that meet the LEICSS case definitions.  Case information 
was also corroborated with the investigating HPT.  In the period of 2015-2018, PHE 
HPTs recorded 1 death in a child in England partly or wholly attributed to lead exposure. 
A case report has since been published, showing the death occurred in a two-year-old 
boy with pica and iron deficiency who had ingested lead-containing paint, resulting in 
acute lead toxicity [13].  Lack of clinician awareness of the association between pica 
and lead exposure was cited as a root cause of the delayed diagnosis and subsequent 
death of the child [13].  Previous research has shown deaths from lead exposure in 
children to be very infrequent in England [17].
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Duration of case investigation 
Of the cases where the investigation had been concluded by the time of data 
extraction for this report (January 2019), the median duration of the investigation 
was 10 weeks, three weeks shorter than the median for 2015-2017. This lower 
duration may be because more 2018 cases were still open (eg under investigation) 
at the time of data extraction, and this may include those with longer duration of 
investigation. 
Table 9.  Duration, in weeks, of the public health investigation of LEICSS 
cases* reported to the surveillance system, England, 2018, 2015-17 
Year Closed Cases/Total cases Median duration (weeks) (LQ-UQ) 
2015-17 102/115 13 (5-23) 
2018 37/45 10 (4-20) 
* Period between date entered onto HP Zone and date case closed on HPZone; cases must have
been closed at date of data extraction from HPZone in January 2019; LQ – Lower Quartile; UQ –
Upper Quartile.
System developments 
Public health intervention level for lead (and laboratory reporting level) 
The public health intervention level for lead has been lowered over time to reflect 
both the gradual decline in population exposure, and the changing knowledge that 
lead exposure in children is associated with toxicity at very low blood 
concentrations. We now know that lead exposure is associated with neuro-
behavioural impairments at blood concentrations of 0.24μmol/L (5μg/dl) and even 
lower [1,18]. Lowering the intervention level for lead would follow international 
precedent set by recommendations in the USA [19], Australia [20], Germany [21], 
France [22] and Wales [23], and would offer benefits of case management to more 
affected children and communities.   
An evaluation conducted by PHE in 2018 recommended that the public health 
intervention level for lead be lowered from ≥10μg/dL (≥0.48μmol/L) to ≥5μg/dL 
(≥0.24μmol/L) and should apply to children aged up to and including 15 years, and 
to pregnant women.  
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This recommendation is based on estimates in pre-school children who have the 
highest BLCs, to maximise the specificity to detect children most likely to benefit 
from public health action. The evaluation concluded that lowering the intervention 
level for lead to ≥5μg/dL (≥0.24μmol/L) would identify children with a BLC in the top 
2% of the population range and would have a net positive impact on health 
inequalities. It is estimated that lowering the intervention level for lead to ≥5μg/dL 
(≥0.24μmol/L) would result in a two to three-fold increase in case notification to 
PHE in the short- to medium- term (provided that there is no change in other 
factors influencing case notification); this should represent only a small absolute 
increase in the number of notifications to a single HPT. A working group has been 
set up to coordinate communication of the new intervention level to stakeholders 
and update the lead action card and LEICSS documentation. It is estimated that 
the new public health intervention level for lead will apply in 2020. An intervention 
level for lead of ≥10μg/dL (≥0.48μmol/L) for non-pregnant adults will remain. 
Invitation of further laboratories to participate in surveillance 
We wrote to laboratories in the UK National External Quality Assessment Scheme for 
Trace Elements (which includes measurement of blood lead concentration) to invite them 
to participate in case reporting to LEICSS in October 2018; six new laboratories have 
agreed to participate (Bristol Southmead, Alder Hey, Royal Liverpool, Northern General 
(Sheffield), Birmingham Heartlands and the private Doctors Laboratory (London)). Other 
UKAS accredited laboratories testing for child BLC are also welcome to participate.   
Governance and procedures 
Following implementation of a permanent surveillance system in 2016 and in 
accordance with the governance framework for other PHE surveillance systems, a 
data sharing agreement was introduced with participating laboratories and a new 
case notification form in 2018.  New procedures were also introduced to enter 
laboratory data onto HPZone and extract it for analysis which reduced the 
requirement to maintain a separate laboratory dataset. Standard Operating 
Procedures for the surveillance were also drafted and updated.  
Alerts for testing for blood lead 
Introduction of an alert on the electronic test request system by Leeds SAS 
laboratory to encourage clinicians to consider testing for blood lead (for those 
children suspected of pica/iron deficiency) increased test requests by 90% since 
2017. We will work with other laboratories to explore the feasibility of 
implementation of a similar model across the SAS laboratory network.   
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Exposure assessment 
Information on exposures in children with elevated BLC is currently captured through a 
questionnaire completed by HPTs on paper or as an electronic document which is 
uploaded to HPZone. This questionnaire will be converted into an online survey format to 
help HPTs explore and scope exposure information and collect relevant information for 
surveillance. A project is also currently underway to update a retrospective survey of 
potential exposures [11] and public health management for cases to incorporate data on 
cases up to the end of 2018.  
PHE’s Environmental Public Health Surveillance System 
The Environmental Public Health Surveillance System (EPHSS) collates and integrates 
data from selected databases on environmental hazard, exposures and health outcome 
data; further details are provided on the PHE website. Development of a lead exposure in 
children module is underway to make LEICSS data available to users. Currently this is 
available to PHE staff, but will eventually be accessible to external users. For access 
please email ephss@phe.gov.uk 
LEICSS outputs 
The following outputs have been produced in relation to LEICSS and its precursors 
between 2014 and 2019. 
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Roberts DJ, Crabbe H, Owodunni T, Gordon-Brown H, Close R, Reshat S, 
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epidemiology from the first three years of a pilot laboratory-based surveillance 
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doi.org/10.1093/pubmed/fdz024. 
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Current and future research and projects 
These include: 
• the SAS laboratory network have requested further guidance on repeat testing
of BLC in children who are already under investigation for elevated lead levels.
We will work with CRCE and NPIS to consider development of additional
guidance
• the Environmental Epidemiology Group at CRCE are working on producing
hazard maps for soil lead concentration, housing age and index of multiple
deprivation to develop a lead exposure model
• the LEICSS working group will work with The British Paediatric Surveillance
Unit and Royal College of Paediatrics and Child Health to deliver a webinar on
lead as part of their series on rare diseases to raise awareness amongst
clinicians
• the PHE Lowering the Lead Intervention Level for Lead working group has
reviewed the resources and guidance required to lower the intervention level
for lead and are working with stakeholders to ensure implementation of the
new intervention level for lead
• the lead exposure questionnaire in use by HPTs to support initial case
management has been reviewed and updated to better scope and capture
potential exposures in cases reported to PHE
• the LEICSS team are developing some case studies for the SAS labs to use in
education and training
• the LEICSS steering group is widening the group of stakeholders who are
consulate/communicated with on a regular basis
Implementation of recommendations since publication of the annual report for 2017 
The following recommendations made in 2018 have been actioned (with current 
progress noted in italics).  
For the LEICSS steering and working group 
Introduce a new case notification form and data sharing agreement with 
laboratories, and new procedures to record laboratory data directly into HPZone 
and extract it for analysis. These measures should improve laboratory data 
recording quality. Case notification forms were updated. Data sharing agreements 
have been signed with most laboratories. SOPs for recording and extracting data 
have been written and put in place. 
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Introduce methods to extract and collate information from the detailed exposure 
questionnaires conducted on lead exposure cases by investigating HPTs, in order 
to collect and analyse data on other potentially important case factors. A new 
online questionnaire has been developed to help HPTs explore potential exposures 
and to capture exposure information. We plan to undertake a look-back exercise to 
explore exposure sources in cases captured by the system so far.  
Survey participating laboratories as to whether they offer laboratory-based systems 
to prompt clinicians to test for lead exposure in children, or undertake awareness 
raising activities in their area, for example as implemented in Leeds SAS laboratory 
[13]. We have worked with the SAS Lab network to identify best practice and 
support the roll out of alerting systems that are planned.  
Monitor the developing evidence on laboratory-based systems to prompt testing of 
children at high risk of lead exposure, for example as implemented in Leeds SAS 
laboratory [13]. As previous point, we support best practice and will monitor the 
impact of changes to laboratory based systems.  
Continue to encourage further laboratories to participate in the surveillance system. 
We wrote to laboratories in the UK National External Quality Assessment Scheme 
for Trace Elements (which includes measurement of blood lead concentration) to 
invite them to participate in case reporting to LEICSS in October 2018; six new 
laboratories have agreed to participate and are now reporting into the surveillance 
system.  
Consider the evidence and arguments for lowering the public health intervention 
level for lead and laboratory reporting BLC to ≥0.24μmol/L (5μg/dl). A PHE working 
group was formed in 2018 and reviewed the evidence for lowering the intervention 
level for lead. Proposals to lower the intervention level are in place and stakeholder 
consultation and communication is being conducted.  
Share the findings of this report with the Royal College of Paediatrics and Child 
Health, and Royal College of General Practitioners to raise awareness amongst 
paediatricians and GPs. The report was sent to these stakeholders and further 
communication with the RCPCH is taking place.  
Develop a broader group of consulting stakeholders including clinical and lay 
(parent and guardian) representatives. A stakeholder mapping exercise was 
conducted and new stakeholders were identified. A consultation and distribution list 
is continuously updated and used to communicate about lead exposures.  
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Recommendations from the annual report for 2018 
For the LEICSS steering and working group 
These groups should: 
• work with the SAS laboratory network to explore implementation of an alert on
the electronic test request system to prompt clinicians to consider blood lead
testing based on the model introduced at  Leeds SAS laboratory [13]
• continue to encourage further laboratories to participate in the surveillance
system
• audit the procedure for managing lead exposure laboratory reports to monitor
and maintain data quality
• develop methods to calculate and describe rates of BLC testing by time, place
and person
• share the findings of this report with the Royal College of Paediatrics and Child
Health, and Royal College of General Practitioners to raise awareness
amongst paediatricians and GPs
• make recommendations to support a survey into the current prevalence of
elevated blood lead levels in children in England
• support PHE to establish a dedicated lead poisoning prevention information
service including web site material and public information leaflets for surgeries
and DIY stores, etc
For laboratories 
• participating laboratories should always notify cases to LEICSS by emailing the
case notification form to phe.leicss@nhs.net
• laboratories interested in participating in the surveillance system should also
email phe.leicss@nhs.net to express their interest
• participating laboratories should be aware that PHE will advise when the new
lower public health intervention level for lead of ≥5μg/dL (≥0.24μmol/L) for
children under 16 years and pregnant women will apply and when to notify
cases at the lower level.
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For PHE Health Protection Teams 
HPTs should: 
• be aware that there is likely a large regional variation in clinician awareness,
testing and reporting practice for lead exposure in children
• determine which laboratories test for lead exposure in children in their
population, and whether the laboratory participates in lead surveillance
reporting
• share this report with local paediatricians and GPs to raise awareness of
sources of lead exposure, children at most risk, and presenting
symptoms/signs of exposure (see box below)
• be aware that the public health intervention level for lead will be lowered from
≥10μg/dL (≥0.48μmol/L) to ≥5μg/dL (≥0.24μmol/L); a briefing note will be
issued to communicate when this change will be implemented.
• encourage clinicians to notify them of children with BLC at or above the public
health intervention level for lead
For clinicians 
Clinicians should: 
• be aware of the most important sources of lead exposure in children (see box,
below)
• be aware of the children at most risk of lead exposure (see box, below), and
have a low threshold for screening these children for lead exposure if they may
have been exposed to lead hazards
• educate parents/guardians of children at risk about prevention of lead
exposure, through the provision of information leaflets etc.
• consider lead exposure as a potential diagnosis in children presenting with
symptoms/signs of acute or chronic lead exposure (see box, below)
• be aware of PHE’s role in managing cases, how to report a case, and of the
case management and surveillance benefits of reporting cases to PHE
• Refer to the Other Resources section, below, for details of how to report a case
of lead exposure, and for resources offering further guidance on case
management
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Box 1. Sources of lead exposure in children, children at most risk of 
exposure, and presentations of lead exposure in children 
Important sources of lead exposure in children: 
• deteriorating leaded paint (particularly houses built prior to early 1970s)
• consumer products (if unregulated): medicines, ceramic cookware, toys
• parental hobbies or occupations (including dust on clothing)
• lead water pipes, and lead from drinking water pipe fittings (i.e. solder) (particularly
houses built prior to early 1970s)
• contaminated soil/land
Children at most risk of lead exposure: 
• children with pica or increased hand to mouth behaviour (eg children with autism or
global developmental delay), particularly with iron deficiency
• children who have recently migrated from countries with less regulation to prevent
lead exposure
• children living in older homes and attending older schools containing leaded paint
Presentations of lead exposure in children: 
• acute exposure resulting in high BLC: anorexia, abdominal pain, constipation,
irritability and reduced concentration, encephalopathy
• chronic exposure [24]:
lower BLCs - mild cognitive and behavioural impairments, may contribute to global
developmental delay, decreased academic achievement, IQ, and specific cognitive
measures (S); increased incidence of attention-related behaviours and problem
behaviours (S), and delayed puberty and decreased kidney function in children ≥12
years of age (L);
higher BLCs - reduced appetite, abdominal pain, constipation, anaemia, delayed
puberty, reduced postnatal growth, decreased IQ, and decreased hearing (S); and
increased hypersensitivity/allergy by skin prick test to allergens and increased
IgE (L).
Where (S) = sufficient evidence and (L) = limited evidence 
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 Other resources
Further PHE resources for the public health management of cases of lead 
exposure: 
• lead pages in the PHE chemicals compendium
https://www.gov.uk/government/publications/lead-properties-incident-
management-and-toxicology
• Lead Action Card (PHE login required)
http://phenet.phe.gov.uk/Resources/duty-doctors/Environmental-
hazards/Chemical%20resources/Lead-action-card-chronic-
exposures.pdf
Resources for clinicians: 
• clinicians with clinical lead exposure queries should consult TOXBASE
or call the National Poisons Information Service, see
https://www.toxbase.org/
Contacts: 
• to notify cases (participating labs only): phe.leicss@nhs.net
• general enquiries: epht@phe.gov.uk
• lead surveillance module in PHE’s Environmental Public Health
Surveillance System: ephss@phe.gov.uk
• to notify cases (direct to a Health Protection Team) find the relevant
Health Protection Team using the residential postcode of the case:
https://www.gov.uk/health-protection-team
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